SSY Group Limited R&D

Technological innovation stands as the cornerstone of SSY's advancement, echoing our commitment to pioneering Chinese intellectual creation. Our group remains steadfast in bolstering investment in fundamental research, expediting the industrialization of cutting-edge technologies, and assimilating world-class innovations and management paradigms. These efforts firmly establish SSY as a trailblazer in the domestic infusion industry.

In our relentless pursuit of excellence, SSY remains attuned to the global medical landscape, intensifying investments in new product research and development. This fervor for innovation has yielded numerous scientific breakthroughs and spearheaded several provincial-level initiatives aimed at industrialization. Our prowess in technological innovation positions SSY as a frontrunner in infusion product development, consistently aligning with international benchmarks.

Annually, SSY embarks on over 10 pioneering projects in chemical innovation and enhanced pharmaceuticals, alongside nearly 100 initiatives focused on generic drug development. Presently, the company boasts two proprietary formulations, three nationally recognized class-three pharmaceuticals, six Chinese medicine protected varieties, and ten national class-five or higher rated new drug products. Notably, SSY oversees 55 chemical substance consistency evaluation projects. With a track record of introducing over 10 new products annually, more than 70% of our sales revenue stems from recent innovations.

At SSY, we are not just shaping the future of healthcare; we are defining it. Join us on our journey of innovation and transformation as we continue to push boundaries and redefine industry standards.